Stock DNA
Pharmaceuticals & Biotechnology
CNY 2,123 Million (Small Cap)
41.00
NA
1.62%
-0.46
4.01%
1.51
Revenue and Profits:
Net Sales:
73 Million
(Quarterly Results - Mar 2026)
Net Profit:
9 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.87%
0%
-3.87%
6 Months
-10.44%
0%
-10.44%
1 Year
3.61%
0%
3.61%
2 Years
-3.37%
0%
-3.37%
3 Years
-26.5%
0%
-26.5%
4 Years
-34.85%
0%
-34.85%
5 Years
-67.76%
0%
-67.76%
Chemclin Diagnostics Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-9.60%
EBIT Growth (5y)
-39.59%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.46
Sales to Capital Employed (avg)
0.27
Tax Ratio
6.36%
Dividend Payout Ratio
39.06%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
22.82%
ROE (avg)
9.87%
Valuation key factors
Factor
Value
P/E Ratio
41
Industry P/E
Price to Book Value
2.20
EV to EBIT
52.99
EV to EBITDA
22.21
EV to Capital Employed
3.17
EV to Sales
6.60
PEG Ratio
NA
Dividend Yield
1.12%
ROCE (Latest)
5.98%
ROE (Latest)
5.37%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
73.30
71.90
1.95%
Operating Profit (PBDIT) excl Other Income
7.30
11.30
-35.40%
Interest
1.40
1.50
-6.67%
Exceptional Items
-0.70
1.20
-158.33%
Consolidate Net Profit
9.00
2.30
291.30%
Operating Profit Margin (Excl OI)
100.00%
-50.10%
15.01%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 1.95% vs -25.26% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 291.30% vs -86.63% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
330.40
429.60
-23.09%
Operating Profit (PBDIT) excl Other Income
92.50
165.70
-44.18%
Interest
6.50
5.30
22.64%
Exceptional Items
-2.40
-3.70
35.14%
Consolidate Net Profit
43.90
127.10
-65.46%
Operating Profit Margin (Excl OI)
94.20%
250.50%
-15.63%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -23.09% vs -2.50% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -65.46% vs -13.77% in Dec 2024
About Chemclin Diagnostics Co., Ltd. 
Chemclin Diagnostics Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






